Towards automation of breast cancer screening

therapixel.com
Entrepreneurs

Matthieu Leclerc-Chalvet
Pierre Fillard

Elaia Team

Laurent Kott

Related articles

Therapixel announces fundraising of 15 Mā‚¬ in series B to deploy MammoScreenĀ® 2D/3D

The Company will accelerate the commercial deployment of its ArtificialĀ Intelligence reading solution for 2D/3D mammography, with a focus onĀ the United StatesĀ 

2022.05.12Ā / 3min read.

Therapixel receives FDA 510(k) clearance for MammoScreenTM

MammoScreenTM, the explainable and actionable artificial intelligence (AI) based software assisting Radiologists in reading screening mammograms, received 510(k) clearance K192854 from the U.S. Food and Drug Administration (FDA).

2020.07.09Ā / 3min read.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.